Inhibrx Biosciences, Inc. reported financial results for Q4 and fiscal year 2025, with net loss of $32.8 million ($2.11 per share) for Q4 and $140.1 million ($9.04 per share) for the year, compared to prior year net loss and net income respectively. Cash and cash equivalents stood at $124.2 million as of December 31, 2025, with $75.0 million gross proceeds from loan amendment on March 18, 2026.
Key takeaways
Net loss $32.8 million or $2.11 per share for Q4 2025 vs $47.9 million or $3.09 per share Q4 2024
Net loss $140.1 million or $9.04 per share for FY 2025 vs net income $1.7 billion or $114.01 basic per share FY 2024
R&D expenses $25.3 million Q4 2025 vs $33.4 million Q4 2024; $113.0 million FY 2025 vs $203.7 million FY 2024
G&A expenses $5.6 million Q4 2025 vs $16.7 million Q4 2024; $23.3 million FY 2025 vs $127.9 million FY 2024
Cash and cash equivalents $124.2 million as of Dec 31 2025; $75.0 million gross proceeds from First Amendment to Loan and Security Agreement with Oxford Finance LLC on March 18 2026
BLA submission for ozekibart in chondrosarcoma to FDA early Q2 2026; INBRX-106 ORR data Q2 2026